Joshua Brody

Biography

Leukemia Lymphoma Society Interview

Immunotransplant for Mantle Cell Lymphoma - ASCO 2011

The Lymphoma Immunotherapy Program at the Mount Sinai School of Medicine and the Brody Lab focus on basic and applied tumor immunology (particularly in lymphoma, melanoma, and ovarian adenocarcinoma). Other areas of interest include: bioinformatic-based collaborations tracking T-cell responses using high-throughput sequencing of the entire TCRbV repertoire and studies of small-molecule inhibitors of lymphocyte signal transduction, e.g. PI3K, mTOR, btk. Our lab has the rare opportunity to both perform correlative studies on primary patient tumor samples from early phase clinical trials and to continually develop advancements in those trials based on what is learned. The core mission is the translation of basic science in tumor immunology into novel clinical trials and development of correlative science associated with those trials to gain a greater understanding of mechanistic-clinical correlates.


PUBLICATIONS:


In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.  Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R. Blood. 2012 Jan 12;119(2):355-63.   PMID: 22045986

Active and passive immunotherapy for lymphoma: proving principles and improving results.  Brody J, Kohrt H, Marabelle A, Levy R. J Clin Oncol. 2011 May 10;29(14):1864-75.  PMID: 21482977

 

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.  Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. Blood. 2011 Feb 24;117(8):2423-32. Epub 2010 Dec 30. PMID:21193697

Idiotype vaccine strategies for treatment of follicular lymphoma.  Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR. Future Oncol. 2011 Jan;7(1):111-22. Review. PMID:21174542

A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors.  Goldstein MJ, Varghese B, Brody JD, Rajapaksa R, Kohrt H, Czerwinski DK, Levy S, Levy R. Blood. 2011 Jan 6;117(1):118-27. PMID: 20876455

 In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.  Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. J Clin Oncol. 2010 Oct 1;28(28):4324-32. PMID:20697067

Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.  Brody J, Levy R. Immunotherapy. 2009 Sep;1(5):809-24. Review. PMID:20636025

Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.  Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Blood. 2009 Jan 1;113(1):85-94. PMID:18812472

A case of complete heart block reverting to normal sinus rhythm after treatment for cardiac invasive Burkitt's lymphoma.  Knowles JW, Elliott AB, Brody J. Ann Hematol. 2007 Sep;86(9):687-90. PMID:17410366

Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma.  Li L, Gupta S, Bashir T, Koduru PR, Brody J, Allen SL. Cancer Genet Cytogenet. 2006 Oct 15;170(2):140-6. PMID: 17011985

Splenic diffuse large B-cell lymphoma ina patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges.  Brody JD, Advani R, Shin LK, Bingham DB, Rosenberg SA. Ann Hematol. 2006 Nov;85(11):817-20. PMID:16937096

Treatment of mantle cell lymphoma: current approach and future directions.  Brody J, Advani R. Crit Rev Oncol Hematol. 2006 Jun;58(3):257-65. Review. PMID:16751087

Using signaling pathways to overcome immune tolerance to tumors.  Engleman EG, Brody J, Soares L.  Sci STKE. 2004 Jul 6;2004(241):pe28. Review. PMID: 15252217

DC-based cancer vaccines: lessons from clinical trials.  Brody JD, Engleman EG. Cytotherapy. 2004;6(2):122-7. Review. PMID: 15203988

CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation. Céfaï D, Schneider H, Matangkasombut O, Kang H, Brody J, Rudd CE. J Immunol. 1998 Mar 1;160(5):2223-30. PMID: 9498761